Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy
- PMID: 14633182
- DOI: 10.1046/j.1365-2893.2003.00456.x
Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy
Abstract
The complex immunological effects of interferon and ribavirin therapy (IFN/R) in hepatitis C virus (HCV) may also exacerbate or trigger the de novo development of autoimmunity. We report the first case of IFN/R therapy associated with Vogt-Koyanagi-Harada disease, a T-cell-mediated autoimmune response to melanocytes. This condition, which has characteristic ocular, neurological and integumentary findings, elicits a systemic prodrome that may mimic side-effect profile and delay of IFN or mask its recognition. We discuss this disease in the context of the known immunomodulatory effects of IFN-alpha and ribavirin and suggest potential mechanistic explanations for the association.
Similar articles
-
Induction of Vogt-Koyanagi-Harada Disease by Interferon-Alpha and Ribavirin Treatment in Patients with Hepatitis C: A Case Report and Review of the Literature.Ocul Immunol Inflamm. 2019;27(2):229-234. doi: 10.1080/09273948.2017.1373827. Epub 2017 Oct 12. Ocul Immunol Inflamm. 2019. PMID: 29023176 Review.
-
[Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection].J Fr Ophtalmol. 2010 Mar;33(3):185-8. doi: 10.1016/j.jfo.2010.01.009. Epub 2010 Feb 20. J Fr Ophtalmol. 2010. PMID: 20172621 French.
-
Vogt-Koyanagi-Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection.J Infect. 2006 Feb;52(2):e59-61. doi: 10.1016/j.jinf.2005.05.005. Epub 2005 Jun 13. J Infect. 2006. PMID: 15951019
-
Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection.Int Ophthalmol. 2010 Oct;30(5):611-3. doi: 10.1007/s10792-010-9357-0. Epub 2010 Feb 23. Int Ophthalmol. 2010. PMID: 20177954
-
Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C.J Gastroenterol. 2004 Nov;39(11):1106-9. doi: 10.1007/s00535-004-1452-4. J Gastroenterol. 2004. PMID: 15580406 Review.
Cited by
-
Interferon therapy in hepatitis C leading to chronic type 1 diabetes.World J Gastroenterol. 2015 Jan 7;21(1):233-9. doi: 10.3748/wjg.v21.i1.233. World J Gastroenterol. 2015. PMID: 25574096 Free PMC article. Review.
-
Organization of the Skin Immune System and Compartmentalized Immune Responses in Infectious Diseases.Clin Microbiol Rev. 2019 Jul 31;32(4):e00034-18. doi: 10.1128/CMR.00034-18. Print 2019 Sep 18. Clin Microbiol Rev. 2019. PMID: 31366611 Free PMC article. Review.
-
Lanreotide treatment in a patient with interferon-associated Graves' ophthalmopathy.Graefes Arch Clin Exp Ophthalmol. 2005 Mar;243(3):269-72. doi: 10.1007/s00417-004-1012-x. Epub 2004 Sep 28. Graefes Arch Clin Exp Ophthalmol. 2005. PMID: 15452720
-
Serous Retinal Detachments Complicating Interferon-α and Ribavirin Treatment in Patients with Hepatitis C.Case Rep Ophthalmol. 2011 Jan;2(1):105-10. doi: 10.1159/000326747. Epub 2011 Mar 12. Case Rep Ophthalmol. 2011. PMID: 22110438 Free PMC article.
-
Ophthalmologic complications of antiviral therapy in hepatitis C treatment.World J Gastroenterol. 2013 Dec 7;19(45):8227-37. doi: 10.3748/wjg.v19.i45.8227. World J Gastroenterol. 2013. PMID: 24363513 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical